LY2090314

製品コードS7063 バッチS706302

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder
1 years -80°C in solvent

化学式

C₂₈H₂₅FN₆O₃

分子量

512.53

CAS No.

603288-22-8

Solubility (25°C)*

体外

DMSO

100 mg/mL (195.11 mM)

Ethanol (warmed with 50ºC water bath)

2 mg/mL (3.9 mM)

Water

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension

CMC-NA

≥5mg/ml

Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 is highly selective towards GSK3 as demonstrated by its fold selectivity relative to a large panel of kinases.
in vitro	LY2090314 selectively inhibits the activity of GSK-3 by interrupting ATP binding. This compound is able to stabilize β-catenin. It shows limited efficacy as monotherapy. This chemical enhances the efficacy in solid tumor cancer cell lines in vitro. ^[1]
in vivo	This compound enhances the efficacy in solid tumor cancer xenografts. ^[1]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	A375 cells
	濃度	20 nM
	反応時間	5 h
	実験の流れ	Cells were treated with various concentrations of this compound for 5 h.
動物実験	動物モデル	Female athymic nude mice
	投薬量	25 mg/kg
	投与方法	i.v

参考

http://meetinglibrary.asco.org/content/82310-102
https://pubmed.ncbi.nlm.nih.gov/25915038/

カスタマーフィードバック

: Data from [Data independently produced by , , Cancer Res, 2017, 77(21):5873-5885]

: Data from [Data independently produced by , , Mol Cancer Ther, 2016, 15(7):1485-94.]

: Data from [Data independently produced by , , Stem Cell Res, 2017, 182-187]

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Proteogenomic characterization of non-functional pancreatic neuroendocrine tumors unravels clinically relevant subgroups [ Cancer Cell, 2025, 43(4):776-796.e14]	PubMed: 40185092
PI3K/AKT signaling mediates stress-inducible amyloid formation through c-Myc [ Cell Rep, 2025, 44(5):115617]	PubMed: 40272983
Cryptotanshinone differentially induces cell death in ATP6V0D1-deficient pancreatic cancer cells [ Cancer Drug Resist, 2025, 8:45]	PubMed: 41019981
Targeting ErbB and tankyrase1/2 prevent the emergence of drug-tolerant persister cells in ALK-positive lung cancer [ NPJ Precis Oncol, 2024, 8(1):264]	PubMed: 39551860
Unveiling the signaling network of FLT3-ITD AML improves drug sensitivity prediction [ Elife, 2024, 12RP90532]	PubMed: 38564252
Development of a live cell assay for real-time monitoring the interactions between the Hippo pathway components 14-3-3 and TAZ [ SLAS Discov, 2024, 29(8):100191]	PubMed: 39510350
Integrin-mediated electric axon guidance underlying optic nerve formation in the embryonic chick retina [ Commun Biol, 2023, 6(1):680]	PubMed: 37391492
Integrin-mediated electric axon guidance underlying optic nerve formation in the embryonic chick retina [ Commun Biol, 2023, 6(1):680]	PubMed: 37391492
Cranial Suture Regeneration Mitigates Skull and Neurocognitive Defects in Craniosynostosis [ Cell, 2021, 184(1):243-256.e18]	PubMed: 33417861
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation [ Nat Commun, 2021, 12(1):2346]	PubMed: 33879767

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。